SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's highly anticipated IPO has triggered intense debate over the company's massive multi-trillion dollar valuation, with investors divided between those betting on long-term AI and orbital infrastructure dominance and skeptics highlighting deep operational losses. The stock is seeing massive trading volume and community speculation regarding upcoming index inclusions and the potential for a long-term liquidity squeeze.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is facing intense volatility as investors debate the legitimacy of the project amid broader market skepticism and comparisons to other political-themed assets. The community remains deeply polarized, with active discussions focusing on potential long-term devaluation, concerns over market manipulation, and the speculative nature of the coin.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring the latest developments in the Middle East and shifting labor market data, driving heightened volatility across major indices. Community discussion is focused on the potential impact of ongoing geopolitical tensions and upcoming economic releases on market momentum.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following news that the company is exploring a potential sale, sparking intense community debate over its valuation and potential suitors among major media and tech firms. Investors are weighing the impact of founder-controlled voting power on deal viability while analyzing the stock's significant move amid broader industry consolidation and ad-platform growth.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a significant pullback, fueled by disappointing May sales data for its flagship drug Yartemlea and fears of potential competition from AstraZeneca. The community is actively debating the reliability of third-party sales data against the company's upcoming J-code reimbursement implementation and regulatory catalysts, while many long-term shareholders are dismissing the volatility as market manipulation and calling for management transparency.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The DJIA is currently a focal point of intense market sentiment as investors weigh conflicting indicators of economic resilience against rising geopolitical tensions, particularly regarding global energy supply routes. Community discourse remains deeply polarized, with active debates centered on whether current market levels represent a sustainable growth trajectory or an overextended bubble vulnerable to sudden shifts in macro policy and international relations.

Investment Managers Series Trust II - Tradr 2X Long SNDK Daily ETF

Tradr 2X Long SNDK Daily ETF

SNXX is trending as traders leverage its 2x exposure to recent massive gains in SanDisk (SNDK), fueled by significant volatility and high-conviction sentiment within the memory chip sector. The community is actively discussing tactical hedging strategies, the impact of a recent forward stock split, and the risks associated with daily leveraged decay during the stock's parabolic run.

Powerlaw Corp. is a closed-end fund, which engages in investing in artificial intelligence, next-generation software, modern aerospace and defense, and consumer technology platforms. It offers daily liquidity, monthly NAV reporting, quarterly portfolio disclosure, independent governance, and the disclosure standards of a registered investment company. The company was founded on September 9, 2024 and is headquartered in San Francisco, CA.

Powerlaw Corp

Powerlaw Corp is currently under intense scrutiny from the community, with shares experiencing high volatility and significant selling pressure despite the fund's heavy exposure to high-profile private companies like SpaceX and OpenAI. Traders are actively debating whether the recent price decline represents a long-term entry opportunity or a potential pump-and-dump scheme, as they await further updates on the fund's net asset value and the impact of upcoming SpaceX-related market events.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh the highly anticipated R2 SUV launch against broader concerns regarding production scaling, profitability, and unfavorable lease pricing. While the community remains deeply divided between bulls citing the long-term potential of the R2 platform and bears focusing on weak execution and cash burn, sentiment is currently pressured by a wider market downturn and skepticism over whether the launch acts as a true turning point.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is seeing a surge in community engagement as investors increasingly view its AI-driven marketing platform and enterprise growth as significantly undervalued relative to peers. The discourse remains highly polarized, with bulls actively advocating for dollar-cost averaging and patience while citing institutional accumulation and upcoming earnings as catalysts for a potential re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock

NLS Pharmaceutics Ltd. (NASDAQ:NCEL - Get Free Report) Director Michel Revel acquired 54,545 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $2.75 per share, with a total value of $149,998.75. Following the completion of the acquisition, the...

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.read more...

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR...

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and...

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression...

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes...

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in...

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute NewcelX Strengthens Scientific Advisory Board...

NewcelX CEO Issues Letter to Shareholders

NewcelX CEO Issues Letter to Shareholders NewcelX CEO Issues Letter to Shareholders PR Newswire ZURICH, Nov. 4, 2025 ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss...

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquarter in Kloten, Switzerland.

Current Price	$3.23
Prev Close	$3.27
Open	$3.29
Dividend Yield	0.00%
50-Day Moving Average	$3.19
Beta	0.72
Avg. Volume	69,370.46
PE Ratio	-0.19

52-Week High	$30.80
52-Week Low	$1.83
Market Capitalization	$17.46M
EPS (Annual)	-$2.16
Price to Book	0.48
Revenue Per Employee	$0.00

NCELNewcelX Ltd.

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest NCEL News